HENDERSON, Nev., Oct. 2, 2023
/PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX)
("Volition"), a multi-national epigenetics company, is taking part
in a webinar hosted by Edison Group, to expound new cancer data to
be presented on October
21st at ESMO 2023, the annual congress of
the European Society for Medical Oncology.
The webinar takes place on Thursday,
October 26th at 10:30
AM U.S. Eastern Time and will include updates from
Volition's Dr. Jake Micallef (Chief
Scientific Officer) and Mr. Gael Forterre (Chief Commercial
Officer), and Dr Andrew Retter, a
leading UK-based Haematologist and Medical Consultant at
Volition.
Dr. Jake Micallef, Chief
Scientific Officer at Volition, said:
"Our upcoming webinar is a timely opportunity to talk through
exciting breakthrough data in our Capture pillar, regarding what we
believe to be an entirely new method for the early detection of
cancer. We will provide stakeholders with deeper insights into the
data we are presenting at ESMO 2023, and outline our next steps
towards commercialization."
The panel and Q&A event is being hosted by Ms. Soo Romanoff, Managing Director of Healthcare at
Edison Group.
Event Details:
Title: Volition Data Insights Webinar
Date: Thursday, October 26,
2023
Time: 10:30 AM U.S
Eastern
Register at: Edison Webinar
To register for Volition's data insights webinar click
HERE. The event will be recorded and available afterward
on-demand.
Volition is developing simple, easy-to-use, cost-effective blood
tests to help diagnose and monitor a range of life-altering
diseases including cancer in both humans and animals. For more
information about Volition's technology go to:
www.volition.com.
About Volition
Volition is a multi-national epigenetics company powered by
Nu.Q®, its proprietary nucleosome quantification platform. Through
its subsidiaries, Volition is developing simple, easy to use, cost
effective blood tests to help diagnose and monitor a range of
life-altering diseases including some cancers and diseases
associated with NETosis such as sepsis and COVID-19. Early
diagnosis and monitoring have the potential to not only prolong the
life of patients but also improve their quality of life. The tests
are based on the science of Nucleosomics™, which is the practice of
identifying and measuring nucleosomes in the bloodstream or other
bodily fluid - an indication that disease is present.
Volition's research and development activities are centered in
Belgium, with an innovation
laboratory and office in the U.S. and additional offices in
London and Singapore.
For more information about Volition's Nu.Q® technology go to:
www.volition.com
The contents found at Volition's website address are not
incorporated by reference into this document and should not be
considered part of this document. This website address is included
in this document as an inactive textual reference only.
Media Enquiries:
Louise Batchelor/Debra Daglish, Volition,
mediarelations@volition.com +44 (0)7557 774620
Safe Harbor Statement
Statements in this press release may be "forward-looking
statements" within the meaning of Section 27A of the Securities Act
of 1933, as amended, and Section 21E of the Securities Exchange Act
of 1934, as amended, that concern matters that involve risks and
uncertainties that could cause actual results to differ materially
from those anticipated or projected in the forward-looking
statements. Words such as "expects," "anticipates," "intends,"
"plans," "aims," "targets," "believes," "seeks," "estimates,"
"optimizing," "potential," "goal," "suggests," "could," "would,"
"should," "may," "will" and similar expressions identify
forward-looking statements. These forward-looking statements relate
to, among other topics, Volition's estimated market
opportunity, the effectiveness of Volition's blood-based
diagnostic, prognostic and disease monitoring tests, and Volition's
ability to develop and successfully commercialize such test
platforms for early detection of cancer and other diseases as well
as serving as a diagnostic, prognostic or disease monitoring tools
for such diseases. Volition's actual results may differ materially
from those indicated in these forward-looking statements due to
numerous risks and uncertainties, including, without limitation,
results of studies testing the efficacy of its tests. For instance,
if Volition fails to develop and commercialize diagnostic,
prognostic or disease monitoring products, it may be unable to
execute its plan of operations. Other risks and uncertainties
include Volition's failure to obtain necessary regulatory
clearances or approvals to distribute and market future products; a
failure by the marketplace to accept the products in Volition's
development pipeline or any other diagnostic, prognostic or disease
monitoring products Volition might develop; Volition's failure to
secure adequate intellectual property protection; Volition will
face fierce competition and Volition's intended products may become
obsolete due to the highly competitive nature of the diagnostics
and disease monitoring market and its rapid technological change;
downturns in domestic and foreign economies; and other risks
identified in Volition's most recent Annual Report on Form 10-K and
Quarterly Reports on Form 10-Q, as well as other documents that
Volition files with the Securities and Exchange Commission. These
statements are based on current expectations, estimates and
projections about Volition's business based, in part, on
assumptions made by management. These statements are not guarantees
of future performance and involve risks, uncertainties and
assumptions that are difficult to predict. Forward-looking
statements are made as of the date of this release, and, except as
required by law, Volition does not undertake an obligation to
update its forward-looking statements to reflect future events or
circumstances.
Nucleosomics™ and Nu.Q® and their respective logos are
trademarks and/or service marks of VolitionRx Limited and its
subsidiaries. All other trademarks, service marks and trade names
referred to in this press release are the property of their
respective owners.
Contact Details:
Louise Batchelor / Debra Daglish
Volition
mediarelations@volition.com
+44 (0)7557 774620
View original
content:https://www.prnewswire.com/news-releases/volition-to-reveal-new-cancer-detection-method-insights-at-upcoming-webinar-301944261.html
SOURCE VolitionRx Limited